Zileuton treatment of AD-like phenotype of the 3xTg mouse model of AD starting at 12 months of age restored mice cognitive abilities and reduced Aβ deposition as well as tau phosphorylation [62]. This evidence concerns the gene MAPT and Alzheimer disease.